rood blauwe elepsis logo Belegger.nl

Spannende tijden GE..

2 Posts
| Omlaag ↓
  1. [verwijderd] 18 augustus 2019 10:35
    Een hedgefund heeft de aanval ingezet op GE, geïnitieerd door Whisleblower Madoff.
    Maar deze man heeft na Madoff al 2x de plank misgeslagen met voorspellingen en zit geldelijk in het Hedgefund dat speculeert op een koersval GE..

    Druipt nogal eigenbelang, Handel in voorkennis, en een zeer stevige belangenverstrengeling vanaf. Blijkt voor 80% tot 90% van het rapport van de whistleblower uit de duim gezogen te zijn, als niet meer. Ik ken zelf iemand toevallig, een expat, die relatief hoog in de boom zit, die dit beaamt..
    Verder is de koers al aardig hersteld van de laag van $ 7,60 en heeft de CEO zelf na dit verhaal net voor 2 miljoen dollar aandelen GE zelf gekocht..

    Handelshuis Goldking geeft een koopaanbeveling mee op de huidige lage koers en heeft zelf ook een positie ingenomen in GE op $ 8,00. In het verleden behaalde resultaten.. ;-)

    Bron: www.cnbc.com/2019/08/16/analyst-nick-...

    MARKETS
    Analyst says GE stock recovering because Madoff whistleblower fraud allegations are baseless
    PUBLISHED FRI, AUG 16 2019 11:56 AM EDTUPDATED FRI, AUG 16 2019 12:56 PM EDT
    Matthew J. Belvedere
    @MATT_BELVEDERE
    KEY POINTS
    “You got the stock on sale yesterday for absolutely no basis. This is why all the insiders are buying,” says William Blair analyst Nick Heymann.
    “This is the last molotov cocktail that someone is throwing down the street,” Heymann says of Harry Markopolos’ allegations against GE.
    In a 175-page report Thursday, Markopolos accused GE of issuing fraudulent financial statements to hide the extent of its accounting problems.

    WATCH NOW
    VIDEO07:56
    General Electric analyst weighs in on the fraud allegations
    The allegations by Madoff whistleblower Harry Markopolos of a $38 billion fraud at General Electric are “at best disingenuous” and “at worst highly inaccurate,” according to Nick Heymann, co-group head of global industrial infrastructure at the William Blair financial services firm.

    “You got the stock on sale yesterday for absolutely no basis. This is why all the insiders are buying,” Heymann told CNBC on Friday, one day after GE shares tanked 11% to $8.01 per share, in their worst trading session in more than a decade.

    GE stock on Friday regained most of the losses after the troubled conglomerate late Thursday revealed that CEO Larry Culp purchased nearly $2 million worth of shares. The purchase was made after Markopolos called the company “a bigger fraud than Enron.”

    Culp, who became chairman and CEO of GE last year, said the Markopolos accusations were false and driven by market manipulation. Leslie Seidman, a GE board director and audit committee chair, also pushed back on the Markopolos report, telling CNBC on Thursday that it “does not reflect the GE that I know.” She added that the report is “full of misleading, inaccurate and inflammatory statements.”

    Earlier Thursday, billionaire investor Stanely Druckenmiller told CNBC that he added to his position in GE, which according to SEC filings already totaled 6.2 million shares. Druckenmiller said he believes in Culp’s turnaround plans.

    In a 175-page report, Markopolos accused GE of issuing fraudulent financial statements to hide the extent of its accounting problems. He told CNBC on Thursday that GE is a bankruptcy waiting to happen. Markopolos, best-known for pointing out irregularities with Bernie Madoff’s investment strategy years before the Ponzi scheme was exposed, also said he conducted the research into GE at the behest of a hedge fund, which he refused to name.

    “The two noncash charges that [Markopolos] alleges should be currently reflected on GE’s balance sheet, which collectively total $18.2 billion, those are not accurate under GAAP accounting,” Heymann said. The company is already cooperating with Justice Department and SEC inquiries into its accounting practices.

    “If this was announced in 2016 or 2017, it would be a very different, real, substantive pulling back of the covers,” argued Heymann. In January 2018, he pointed out, GE’s long-term care insurance unit had to boost reserves by $15 billion. Markopolos claims another $18.5 billion of insurance loss reserves are needed.

    Admitting he’s not knowledgeable enough to say either way whether Markopolos is correct about the $18.5 billion, Heymann said GE could easily afford that amount if it were required.

    “The immediate liquidity of the company — unrestricted cash, revolving lines less commercial paper outstanding — is over $60 billion. That’s write a check,” Heymann said. He added that GE would be getting $21.4 billion in the fall from the BioPharma sale, and could sell its health-care unit for about $46 billion and the rest of Baker Hughes for $5.5 billion. “That gives you a $133 billion of intermediate-term cash liquidity to address an $18.5 billion alleged requirement,” Heymann calculated.

    “This is the last Molotov cocktail that someone is throwing down the street,” Heymann said of the Markopolos report, suggesting it’s a desperate attempt to disparage GE for profit.

    In a note to William Blair clients, Heymann wrote, “We do not believe GE’s financial statements purposely misrepresent the company’s current financial condition and future potential liabilities. We find it hard to believe that GE, which has been engaged with several regulatory reviews of its accounting and financial disclosures for over two years, has fraudulently misrepresented its financial reporting.”

    Heymann was among a number of analysts on Friday who were defending GE following the Markopolos report.

2 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.124
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.226
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.892
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.849
Aedifica 3 926
Aegon 3.258 323.087
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.906
Agfa-Gevaert 14 2.064
Ahold 3.538 74.353
Air France - KLM 1.025 35.295
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.051
Alfen 16 25.316
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 425
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.988
AMG 972 134.478
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.063
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.035 321.004
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.631
ASML 1.766 110.402
ASR Nederland 21 4.513
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.978
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449